Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 6/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336319 | 0.75 | LMNA (0.45) | LMNAFDPSPGK1PGK2CA2 | |
| SCHEMBL10580976 | 0.75 | LMNA (0.45) | LMNAFDPSPGK1PGK2CA2 | |
| SCHEMBL27006289 | 0.72 | LMNA (0.56) | LMNAFDPSPGK1PGK2CA2 | |
| SCHEMBL11165245 | 0.71 | LMNA (0.36) | LMNAFDPS | |
| SCHEMBL8563422 | 0.71 | ALDH1A1 (0.41) | LMNAFDPS | |
| SCHEMBL8563414 | 0.71 | LMNA (0.41) | LMNAFDPSPGK1PGK2CA2 | |
| SCHEMBL10544288 | 0.69 | LMNA (0.39) | LMNAFDPSPGK1PGK2 | |
| SCHEMBL28490987 | 0.69 | LMNA (0.39) | LMNAFDPSPGK1PGK2 | |
| SCHEMBL992 | 0.69 | DGAT1 (0.41) | LMNAFDPSPGK1PGK2CA2 | |
| SCHEMBL16216680 | 0.69 | LMNA (0.45) | LMNAFDPSPGK1PGK2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531648-B | Herbicidal compounds | 先正达参股股份有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-8198308-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2041116-A1 | PHENYL SUBSTITUTED HETEROARYL-DERIVATIVES AND USE THEREOF AS ANTI-TUMOR AGENTS | Boehringer Ingelheim International GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
| WO-2008003770-A1 | PHENYL SUBSTITUTED HETEROARYL-DERIVATIVES AND USE THEREOF AS ANTI-TUMOR AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
| EP-1309405-B1 | METHOD FOR CARRYING OUT A CHEMICAL REACTION | CHEMSPEED TECHNOLOGIES AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| US-6815463-B2 | FOR THERAPY OF DISEASE OF CELLULAR HYPERPROLIFERATION IN A SUBJECT | KOSAN BIOSCIENCES, INC. | 2004-11-09 | — | — | US | disclosed |
| WO-2004026245-A2 | SUBSTITUTED PHOSPHONATE COMPOUNDS HAVING BONE ANABOLIC ACTIVITY | ILEX ONCOLOGY RESEARCH, SARL (CH) | 2004-04-01 | — | — | WO | disclosed |
| US-6670389-B2 | Useful for treating cellular hyperproliferation | KOSAN BIOSCIENCES, INC. | 2003-12-30 | — | — | US | disclosed |
| EP-1358186-A1 | LAULIMALIDE DERIVATIVES | Kosan Biosciences, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20030195181-A1 | Laulimalide derivatives | ASHLEY GARY (US) | 2003-10-16 | — | — | US | disclosed |
| US-20020128471-A1 | Useful for treating cellular hyperproliferation | KOSAN BIOSCIENCES, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002064589-A1 | LAULIMALIDE DERIVATIVES | KOSAN BIOSCIENCES, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-0351214-A1 | Anti-inflammatory aryl derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-17 | — | — | EP | disclosed |
| US-4766213-A | 1,4-dihydropyridines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-08-23 | — | — | US | disclosed |
| EP-0237695-A2 | 1,4-Dihydropyridines | MERCK PATENT GmbH (DE) | 1987-09-23 | — | — | EP | disclosed |
| EP-0210571-A1 | Phosphonopyridines and their 1,4-dihydroderivatives | BOEHRINGER BIOCHEMIA ROBIN S.p.A. (IT) | 1987-02-04 | — | — | EP | disclosed |
| US-4073934-A | Novel acetylenic prostaglandin analogs | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195181-A1 | Laulimalide derivatives | NFATC1, MCL1, CYP51A1 | LMNA 246/4885FDPS 78/4885PGK1 1550/4885 |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | LMNA 294/4885FDPS 1328/4885PGK1 2006/4885 |
| US-20020128471-A1 | Useful for treating cellular hyperproliferation | MKI67, NFATC1, PCNA | LMNA 183/4885FDPS 408/4885PGK1 763/4885 |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | LMNA 294/4885FDPS 1328/4885PGK1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.